Effect of Androgel [testosterone] on atherogenesis, inflammation, cardiovascular risk factors and adiposity in type 2 diabetic males with hypogonadotrophic hypogonadism: A prospective, randomized and controlled-study
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 02 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 02 Nov 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.